Oral Answers to Questions

Preet Kaur Gill Excerpts

Wednesday 10th June 2020 Commons Chamber

[Anne-Marie Trevelyan]

It is lovely to welcome a scientist to our Green Benches. As my hon. Friend suggests, organisations right across the UK are playing a vital role in innovating to develop a coronavirus vaccine. It is a great pleasure to thank all the communities across the island of Ynys Môn helping to fight coronavirus with their technological solutions. My officials are also working closely with the Action for Global Health network to draw on the expertise of a range of UK charities and organisations as part of our approach to shaping global vaccine efforts. If UK-backed candidates for vaccines are successful, the Department for International Development funding for international efforts will help to ensure that those are scaled up and support equitable access for all who need them globally.

[Preet Kaur Gill (Birmingham, Edgbaston) (Lab/Co-op)]

Happy birthday, Mr Speaker.

I start by welcoming the Secretary of State’s apology concerning the sharing of an unacceptable, offensive and xenophobic image, but it was extremely disappointing that it took so long to apologise.

The Secretary of State has said she wants to ensure equitable access for many new vaccines once developed. AstraZeneca has guaranteed the US and the UK the first 400 million of any new vaccine in September, while those in the world’s poorest countries will not begin to get any until the end of the year, at the very earliest. Does she think this is equitable access?

[Anne-Marie Trevelyan]

The vaccine challenge, and the race for scientists to crack that code and for industry to come in behind them to support, to produce and to deliver, is critical. AstraZeneca is leading the way with us and has now signed a licence for 300 million doses, should the Oxford vaccine be successful, which it has committed will go to low and middle-income countries, which is fantastic news. This is a huge piece of work, which is led by the Department for Business, Energy and Industrial Strategy and which DFID is involved in, to draw together that scientific effort. The key point about any vaccine that is found—obviously we hope one will be found—is delivery, which is why Gavi, the Vaccine Alliance is so critical, because it can reach out. It has effective networks for delivering vaccines in those poorest countries, where we want to make sure that everyone who needs it gets that vaccine.

[Preet Kaur Gill]

The “Oxford Dictionary” defines “equitable” as “fair or just”; what the Secretary of State has just outlined is neither. She rightly praises Gavi and the number of people it has vaccinated, but as she knows the alliance would not be needed if access to vaccines was actually equitable. There is a disconnect between the Government’s rhetoric on this issue and their actions. Rather than outsourcing responsibility, will she step up and commit to attaching clear, transparent conditions on British taxpayers’ money to accelerate development and guarantee truly equitable access to vaccines based on need, not how deep your pockets are?

[Anne-Marie Trevelyan]

The UK taxpayer, through UK aid, has made a huge commitment. We gave £250 million to CEPI very early on in the crisis. Those who use that CEPI money as part of their vaccine development work have that commitment. That is fantastic. Gavi is a fundamental part of ensuring the whole world works together to make vaccines available. By being the organisation that vaccinates nearly 50% of the world’s children, it brings down prices. It can bring huge negotiating benefits so the value is spread across the world.